Parkinson's Disease RNA Therapeutics Companies
Overview
flowchart TD
therapeutics["therapeutics"] -->|"protects against"| age_related_cognitive_decline["age-related cognitive decline"]
therapeutics["therapeutics"] -->|"inhibits"| neuroinflammation["neuroinflammation"]
Therapeutics["Therapeutics"] -->|"references"| SIRT6["SIRT6"]
Therapeutics["Therapeutics"] -->|"references"| AADC["AADC"]
Therapeutics["Therapeutics"] -->|"references"| CX3CR1["CX3CR1"]
Therapeutics["Therapeutics"] -->|"references"| BACE1["BACE1"]
Therapeutics["Therapeutics"] -->|"references"| APOE["APOE"]
Therapeutics["Therapeutics"] -->|"references"| VCP["VCP"]
Therapeutics["Therapeutics"] -->|"references"| GFAP["GFAP"]
Therapeutics["Therapeutics"] -->|"references"| NURR1["NURR1"]
Therapeutics["Therapeutics"] -->|"references"| BDNF["BDNF"]
Therapeutics["Therapeutics"] -->|"references"| NLRP3["NLRP3"]
Therapeutics["Therapeutics"] -->|"references"| TFEB["TFEB"]
Therapeutics["Therapeutics"] -->|"references"| PPARGC1A["PPARGC1A"]
style therapeutics fill:#4fc3f7,stroke:#333,color:#000
This page catalogs biotechnology and pharmaceutical companies developing RNA-based therapeutics for Parkinson's Disease (PD), including antisense oligonucleotides (ASOs), small interfering RNA (siRNA), and other RNA-targeting modalities. These approaches aim to directly modulate the expression of genes implicated in PD pathogenesis, including [LRRK2](/genes/lrrk2), [alpha-synuclein (SNCA)](/genes/snca), and [GBA](/genes/gba)[@rnainvest2024].
...Parkinson's Disease RNA Therapeutics Companies
Overview
Mermaid diagram (expand to render)
This page catalogs biotechnology and pharmaceutical companies developing RNA-based therapeutics for Parkinson's Disease (PD), including antisense oligonucleotides (ASOs), small interfering RNA (siRNA), and other RNA-targeting modalities. These approaches aim to directly modulate the expression of genes implicated in PD pathogenesis, including [LRRK2](/genes/lrrk2), [alpha-synuclein (SNCA)](/genes/snca), and [GBA](/genes/gba)[@rnainvest2024].
RNA therapeutics represent a promising disease-modifying approach for PD because they can:
- Directly target the underlying genetic causes of disease
- Achieve precise allele-specific targeting where relevant
- Provide long-lasting effects with periodic dosing
- Potentially modify disease progression rather than just treating symptoms
Companies with Active PD RNA Programs
| Company | Technology | Primary PD Targets | Development Stage | Key Partnerships |
|---------|------------|-------------------|-------------------|------------------|
| [Ionis Pharmaceuticals](/companies/ionis) | ASO | LRRK2, GBA | Phase 1/Preclinical | Biogen |
| [Wave Life Sciences](/companies/wave-life-sciences) | Stereopure ASO | Alpha-synuclein | Preclinical | Takeda |
| [Alnylam Pharmaceuticals](/companies/alnylam) | siRNA | LRRK2, GBA | Discovery | Regeneron |
| [RNP Inc.](/companies/rnp-inc) | RNAi/ASO | Alpha-synuclein | Discovery | None disclosed |
| [Arrowhead Pharmaceuticals](/companies/arrowhead) | RNAi (TRiM™) | Alpha-synuclein | Preclinical | Various |
| [Biogen](/companies/biogen) | ASO | LRRK2, Alpha-synuclein | Phase 1 | Ionis |
Antisense Oligonucleotide (ASO) Companies
Ionis Pharmaceuticals
Pipeline:
- BIIB132 (LRRK2 ASO): Targeting LRRK2 mRNA for reduction in LRRK2-associated PD. Currently in Phase 1 development through Biogen partnership.
- IONIS-GBA2: ASO targeting glucocerebrosidase modulation for GBA-associated PD. Preclinical stage.
Ionis pioneered the ASO platform and has strategic partnership with Biogen for neurological disease programs. Their ASOs are delivered via intrathecal injection and work through RNase H-mediated mRNA degradation.
Key Reference: [@ionispipeline]
Wave Life Sciences
Pipeline:
- WVE-101 (Alpha-synuclein ASO): Targeting SNCA mRNA for reduction of alpha-synuclein protein. Preclinical stage.
Wave uses proprietary stereopure chemistry that provides precise control over oligonucleotide stereochemistry, potentially improving potency and reducing off-target effects compared to stereorandom mixtures.
Key Reference: [@wavepipeline]
Biogen
Pipeline:
- BIIB122: LRRK2 ASO (from Denali partnership) - now in late-stage development
- BIIB080: Tau ASO (Ionis partnership) - Alzheimer's, not PD-specific
- ABBV-951: Alpha-synuclein antibody - not RNA-based but in pipeline
Biogen has the broadest neuroscience RNA program through its Ionis partnership and acquired LRRK2 program from Denali.
siRNA Companies
Alnylam Pharmaceuticals
Pipeline:
- ALN-LRRK2: siRNA targeting LRRK2 expression. Discovery stage.
- ALN-GBA: siRNA targeting GBA1 for GBA-associated PD. Discovery stage.
Alnylam's RNAi platform has produced five FDA-approved drugs. Their CNS delivery approach uses the TRiM™ platform and intrathecal injection for neurological diseases.
Key Reference: [@alnylampipeline]
Arrowhead Pharmaceuticals
Pipeline:
- ARO-SNCA: Targeting alpha-synuclein expression. Preclinical research stage.
Arrowhead's TRiM™ platform enables tissue-specific delivery. They are exploring lung delivery as a route to CNS via neural pathways and have collaborations for CNS-targeted programs.
RNP Inc.
Pipeline:
- RNP-501: RNAi targeting alpha-synuclein for PD. Discovery stage.
- RNP-502: siRNA targeting LRRK2. Research stage.
RNP is a Japanese biotech focused on RNA-based therapeutics for neurodegenerative diseases, with technology for both ASO and RNAi modalities.
mRNA Therapeutics for PD
mRNA therapeutics for PD remain largely in preclinical research. Potential applications include:
- Delivering mRNA encoding neuroprotective proteins (e.g., GDNF, NRTN)
- Restoring deficient enzyme function (e.g., GCase for GBA carriers)
- Creating induced dopamine neurons via transcription factor expression
Currently no companies have entered clinical trials with mRNA therapeutics specifically for PD, though this represents an emerging area.
Therapeutic Target Overview
LRRK2 Targeting
[LRRK2](/genes/lrrk2) mutations are the most common genetic cause of familial PD. RNA therapeutics can reduce LRRK2 protein expression:
| Company | Modality | Program | Stage |
|---------|----------|---------|-------|
| Ionis/Biogen | ASO | BIIB132 | Phase 1 |
| Alnylam | siRNA | ALN-LRRK2 | Discovery |
| Denali | Small molecule | DNL151/DNL122 | Phase 2b |
Alpha-Synuclein Targeting
[Alpha-synuclein](/proteins/alpha-synuclein) aggregation is central to PD pathogenesis. RNA approaches can reduce SNCA expression:
| Company | Modality | Program | Stage |
|---------|----------|---------|-------|
| Wave Life Sciences | ASO | WVE-101 | Preclinical |
| Arrowhead | siRNA | ARO-SNCA | Preclinical |
| RNP Inc. | RNAi | RNP-501 | Discovery |
GBA Targeting
[GBA](/genes/gba) mutations are a significant risk factor for PD. RNA therapeutics can modulate GCase expression:
| Company | Modality | Program | Stage |
|---------|----------|---------|-------|
| Ionis | ASO | IONIS-GBA2 | Preclinical |
| Alnylam | siRNA | ALN-GBA | Discovery |
Delivery Challenges
RNA therapeutics face significant challenges for CNS indications[@pdclinicaltrials]:
Blood-Brain Barrier (BBB): Most RNA therapeutics require intrathecal delivery or specialized delivery systems
Distribution: Ensuring adequate coverage of target brain regions
Durability vs. Safety: Balancing duration of effect with ability to reverse if needed
Off-target effects: Minimizing unintended gene silencingCurrent delivery approaches:
- Intrathecal injection: Direct delivery to cerebrospinal fluid (used by Ionis, Biogen)
- Conjugate systems: GalNAc for liver, exploring CNS-targeted conjugates
- Viral vectors: AAV for long-term expression (more common for gene therapy than RNA)
- Exosomes: Emerging delivery vehicles for CNS
Clinical Trial Landscape
Currently, no RNA therapeutics have reached late-stage clinical trials specifically for PD. The field is at early stages with several programs in Phase 1 or preclinical development.
Active/Recent PD RNA Trials:
- NCT06133089: BIIB132 (LRRK2 ASO) - Phase 1
- Various discovery programs expected to enter IND-enabling studies 2025-2026
Investment and Partnerships
The PD RNA therapeutics space has seen significant investment:
| Company | Partner | Deal Value | Focus |
|---------|---------|------------|-------|
| Ionis | Biogen | $2B+ | Neuroscience ASO |
| Alnylam | Regeneron | $2B | CNS RNAi |
| Wave | Takeda | $2.6B | CNS ASO |
| Arrowhead | Janssen | $3.7B | RNAi platform |
Cross-References
Related Therapeutic Pages
- [siRNA Therapy for Parkinson's Disease](/therapeutics/sirna-therapy-parkinsons)
- [ASO Therapy for Parkinson's Disease](/therapeutics/aso-therapy-parkinsons)
- [Antisense Oligonucleotide Therapy for Neurodegeneration](/mechanisms/antisense-oligonucleotide-therapy-neurodegeneration)
Related Gene/Protein Pages
- [LRRK2 Gene](/genes/lrrk2)
- [SNCA Gene (Alpha-Synuclein](/genes/snca))
- [GBA Gene](/genes/gba)
- [Alpha-Synuclein Protein](/proteins/alpha-synuclein)
Related Company Pages
- [PD Pipeline Overview](/companies/pd-pipeline)
- [PD Pipeline Companies](/companies/pd-pipeline-companies)
- [RNA Therapeutics Investment Landscape](/investment/rna-therapeutics-neurodegeneration)
References
[Alvarez-Ercava et al., RNA therapeutics in Parkinson's disease (2019)](https://doi.org/10.1016/j.neuropharm.2019.04.030)
[Ionis Neuroscience Pipeline](https://www.ionispharma.com/pipeline/)
[Alnylam Pipeline Overview](https://www.alnylam.com/pipeline/)
[Wave Life Sciences Pipeline](https://ir.wavelifesciences.com/pipeline)
[ClinicalTrials.gov PD RNA Search](https://clinicaltrials.gov/search?cond=Parkinson%27s+disease&intr=RNA)